Physician profile
Mojan Gabbay
NPI 1447277371
$3,593.11
in general payments reported to CMS, 2019-2025
36 companies · $825 in 2025
The $825 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $147 · 2021: $620 · 2022: $510 · 2023: $526 · 2024: $554 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.27 | 2019-2025 | |
| Pfizer INC. | $248.09 | 2022-2025 | |
| Exact Sciences Corporation | $219.06 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $182.14 | 2021-2022 | |
| Hologic Sales and Service, LLC | $179.01 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Exeltis, USA INC. | $168.14 | 2020-2025 | Slynd |
| Lilly USA, LLC | $142.77 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Sage Therapeutics, LLC | $141.90 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $139.27 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.85 | 2019-2025 | |
| Aspira Women'S Health INC | $105.03 | 2021-2023 | Ova1 |
| Baxter Healthcare | $103.86 | 2022-2025 | Perclot |
| Merck Sharp & Dohme LLC | $90.09 | 2019-2021 | |
| Novo Nordisk INC | $85.51 | 2019-2025 | Ozempic, Rybelsus |
| Coopersurgical, INC. | $82.56 | 2025 | Paragard T 380a |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.70 | 2019-2025 | |
| Myovant Sciences INC. | $78.24 | 2022 | |
| Abbott Laboratories | $71.95 | 2023-2024 | Proclaim, Eterna |
| Sumitomo Pharma America, INC. | $67.93 | 2023-2025 | Myfembree |
| Mannkind Corporation | $53.78 | 2019-2020 | |
| Astellas Pharma US INC | $50.38 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.05 | 2021-2022 | |
| Amgen INC. | $48.57 | 2023-2024 | Prolia, Evenity, Otezla |
| Mimedx Group, INC. | $46.64 | 2024 | |
| Glaxosmithkline, LLC. | $45.67 | 2021-2024 | Shingrix, Arexvy |
| Genzyme Corporation | $38.49 | 2023 | |
| Becton, Dickinson and Company | $33.15 | 2022-2024 | Bd Max System, Bd Max Instrument |
| Therapeuticsmd, INC. | $32.41 | 2021 | |
| Aimmune Therapeutics, INC. | $31.74 | 2025 | Vowst |
| Zealand Pharma US, INC. | $20.59 | 2021 | |
| Scynexis, INC. | $20.30 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.50 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $19.41 | 2024 | Twirla |
| Biosense Webster, INC. | $18.60 | 2021 | |
| Evofem Biosciences, INC. | $16.46 | 2025 | Phexxi, Solosec, Phexx |
| Lupin INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mojan Gabbay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.